Multiple reports have shown that low absolute lymphocyte count at day 30 (ALC30) after allogeneic hematopoietic SCT (AHSCT) is associated with higher risk of disease relapse and worse OS. However, these reports included heterogeneous populations with different grafts and GVHD prophylaxis. Therefore, we retrospectively evaluated the association of ALC30 with transplant outcomes in a cohort of 381 consecutive patients who underwent AHSCT between 2005 and 2010 and received T-replete PBSC grafts and Tacrolimus/Mycophenolate combination as GVHD prophylaxis. Median follow-up was 57 months. Lower ALC30 (⩽400 × 10 6 /L) was associated with lower OS and increased nonrelapse mortality (NRM) for the whole cohort as well as for recipients of SD and UD grafts separately. Lower ALC30 was associated with more severe acute GVHD (aGVHD; III-IV) for the entire cohort as well as for the SD and UD groups. No association was found between lower ALC30 and relapse. Pretransplant factors associated with lower ALC30 were: unrelated donors; HLA mismatch; older donors; lower recipient age; and lower CD34+ cell dose. In this large retrospective study, ALC30 ⩽ 400 × 10 6 /L was associated with worse OS, increased NRM and severe aGVHD.
INTRODUCTION
Advances in supportive care and preparative regimens in allogeneic hematopoietic SCT (AHSCT) have reduced transplantrelated complications and extended this therapeutic modality to both older and less-fit patients, with an overall increase in the number of transplants per year. GVHD and relapse continue to be the two major complications that limit long-term success. Although the use of DLI in some patients who relapse after AHSCT can result in disease remission, DLI may increase the risk of acute GVHD (aGVHD). [1] [2] [3] [4] [5] These findings have led to an interest in the kinetics of post-transplant lymphocyte recovery as a surrogate for effective immune reconstitution and as a predictor of transplant outcomes.
Initial retrospective reports by Powel, Kumar, and Ishaqi et al. have primarily evaluated patients who underwent allogeneic BM transplants (T-replete) from HLA-matched sibling donors (SD), using calcineurin inhibitor ± MTX for GVHD prophylaxis. They showed that high absolute lymphocyte count (ALC) in the first 21-30 days post transplant was associated with less relapse and improved relapse-free survival. [6] [7] [8] [9] Subsequently, Savani et al. 10 reported on 157 patients who underwent AHSCT with ex-vivo T-cell-depleted PBSC grafts from SD, with tacrolimus (Tac)/MTX GVHD prophylaxis. He showed that early ALC recovery correlated not only with less risk of relapse, but also with less risk of aGVHD, nonrelapse mortality (NRM) and improved OS. Considering that the above literature was all in SD transplant, the impact of day-30 ALC (ALC30) on post-transplant outcomes in recipients of unrelated donor (UD) grafts is less clear. So far, only one report described the significance of ALC following AHSCT from UD. Le Blanc et al. 11 reported on 102 patients, who received PBSC with invivo T-cell depletion (Thymoglobulin, OKT3 or Alemtuzumab) as part of their GVHD prophylaxis. She showed that early ALC recovery correlated with less NRM, and better disease-free survival in multivariate analysis. In univariate analysis, high ALC30 was associated with less aGVHD, without an association with relapse.
It is difficult to compare all the results from the above literature owing to lack of uniformity with regard to graft source and composition (BM vs PBSC, SD vs UD and T-replete vs T-deplete). In addition, variable ALC values at various times post transplant were used to evaluate the correlation of ALC with clinical outcomes post AHSCT. Therefore, we sought to evaluate the outcome correlation of ALC30 in a relatively large cohort of patients who uniformly received T-replete PBSC from SD and UD with Tac/ mycophenolate mofetil (MMF) as GVHD prophylaxis. We show that lower ALC30 was associated with higher risk of severe aGVHD, NRM and higher overall mortality.
MATERIALS AND METHODS
We retrospectively evaluated a cohort of 414 consecutive patients who received AHSCT between January 2005 and August 2010 at Karmanos Cancer Center (Detroit, MI, USA). Patients with aGVHD or death before day-30 post-transplant were excluded from the analysis (N = 33). All patients received Tac/MMF for GVHD prophylaxis. This study was approved by Wayne State University Institutional Review Board. The primary end point 1 of this study was to evaluate the association between ALC30 ⩽ 400 × 10 6 /L and AHSCT outcomes including OS, GVHD, NRM and relapse. We also evaluated pretransplant donor, recipient and regimen related factors' associations with ALC30. Our own preliminary exploratory univariate analysis showed positive correlation between ALC ⩽ 400 × 10 6 /L and worse survival. Therefore we used this ALC 400 × 10 6 /L number in the multivariate analysis. 12, 13 Inclusion and exclusion criteria All patients with a diagnosis of hematologic malignancies, including myelodysplastic syndromes (MDS) and myeloproliferative disorders (MPD), were included in the study. Patients had a suitable HLA 8/8 (A, B, C and DR) or 7/8 matched SD or UD based on high-resolution molecular typing. Patients were selected for transplant based on our institutional guidelines.
14 Exclusion criteria were: patients who underwent AHSCT for aplastic anemia; patients who had stem cells from cord blood or haploidentical donor. As we wanted to evaluate a uniform regimen for GVHD prophylaxis, patients who received thymoglobulin were excluded. Our objective was to find an early enough and commonly used biomarker (day-30 ALC), which can predict subsequent transplant outcomes and potentially allow for interventions to modify these outcomes. Furthermore, as systemic steroids used to treat aGVHD are lympholytic, this will introduce yet another confounding factor to day-30 ALC. Therefore we excluded patients who died or had aGVHD before day-30 post transplant (30 out of 414 patients in our cohort). For those patients who underwent more than one AHSCT, we used data from the first transplant only.
Disease diagnosis/risk definitions, preparative regimens, GVHD prophylaxis and supportive care
Diseases at high risk for relapse and death post transplant were defined primarily based on the Center for International Blood and Marrow Transplant Research criteria, with few additions (based on published literature). [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] The choice of preparative regimen was based on disease diagnosis, status, age, co-morbidities at the discretion of the treating physician. These were: Full intensity including Bu/Flu (BU and Fludarabine), BEAM ± R (Carmustine, Etoposide, Ara C, Melphalan (Mel) ± Rituximab), TBI/ VP16 (TBI and etoposide), CBV (CY, Carmustine and etoposide) BAC (Bu, Ara C and CY) and reduced intensity regimens including Bu/Flu/TBI ± R, Flu/ Mel/TBI ± R and Flu/CY/TBI. GVHD prophylaxis was with Tac/ MMF. Tac was started intravenously at day − 3 (0.03 mg/kg/day) to achieve trough blood levels of 10-15 nmol/L, then tapered by day +60 and discontinued by day +180. Oral MMF was initiated at 10 mg/kg (based on adjusted weight) every 8 h starting day − 3 and discontinued without tapering on day +30. All AHSCT recipients received G-CSF 5 μg/kg starting at day +6 until engraftment. Antimicrobial prophylaxis consisted of norfloxacin, acyclovir and fluconazole. Pneumocystis prophylaxis was started day 21 post transplant with double strength trimethoprim/sulfamethoxazole administered twice weekly. Management of aGVHD was at the discretion of the treating physician. The details of relapse risk definitions, preparative regimens, GVHD prophylaxis and supportive care have been described elsewhere. 14 
Statistical analysis
The choice of cutpoint for ALC was first determined by our group's preliminary exploratory univariate analysis, which showed positive correlation between ALC ⩽ 400 × 10 6 /L and worse survival. Therefore we chose ALC 400 × 10 6 /L for all multivariate analyses. 12, 13 In addition, using methods already established for selection of cutpoints, 26 we explored whether 400 × 10 6 /L was the correct cutpoint given this new data set. 27 We looked at a range of values from 100 × 10 6 /L to 1000 × 10 6 /L in increments of 50 × 10 6 /L and calculated P-values for ALC and Akaike information criterion (AIC) for the adjusted Cox model for OS. AIC is a measure of the relative quality of a statistical model for a given set of data. It deals with the trade-off between the goodness of fit of the model and the complexity of the model. The preferred model is the one with the minimum AIC value. In addition, using the model adjusted for other variables of interest will eliminate the potential influence of other factors on the choice of a cutpoint. All explored levels of ALC cutpoints from 100 to 1000 × 10 6 /L resulted in significant P-values ranging from o 0.0001 to 0.0238, respectively. Model-fit outcomes of AIC ranged from 2174.46 to 2194.74, with the lowest (optimal) AIC value occurring at 400 × 10 6 /L. Therefore, the choice of 400 × 10 6 /L cutpoint is justified given previous pilot work and that it also resulted in optimization of the multivariable survival model given all other cutpoints as it resulted in the lowest AIC.
Differences between baseline characteristics, as well as clinical outcomes were compared between SD and UD groups using Fisher's exact test for categorical variables and Wilcoxon rank-sum tests for continuous variables. Competing risks Cox proportional hazard models were used to assess the association of ALC30 with transplant outcomes including OS, NRM, aGVHD, cGVHD, CMV reactivation and relapse. All analyses were adjusted for donor/recipient age, sex, CMV status, HLA mismatch, CD34+ cells, regimen intensity and relapse risk. Multivariate logistic regression analysis was also performed to determine any pretransplant donor/recipient associations with ALC values ⩽ 400 × 10 6 /L at day 30. Cumulative incidence curves were also constructed for these various outcomes, and Kaplan-Meier curves for OS between the groups. The data analysis for this paper was generated using SAS software, Version 9.3 of the SAS System for Windows (Cary, NC, USA).
RESULTS

Patient characteristics
Patient characteristics are described in Table 1 . Of 381 patients, there were 190 recipients of UD grafts and 191 patients who received AHSCT from SD. There were no significant differences between the UD and SD groups in regard to the distribution of disease diagnosis, conditioning regimen, disease risk, donor/ recipient CMV status, stem cell source and number of prior transplants. There were more female donors, older donors and recipients in the SD group (P = 0.03, o 0.0001 and o0.0001, respectively), whereas there were more HLA mismatches and higher median CD34+ cell dose infused in the UD group (P ⩽ 0.0001 for both outcomes).
Transplant outcomes
The median follow-up for surviving patients in both groups was 57 months. Transplant outcomes are described in Table 2 . Median day for neutrophil engraftment was 11 post transplant. Three patients in UD group died of graft failure. There was a trend toward higher cumulative incidence (incidence) of aGVHD grades (II-IV) in the UD compared with SD group (58% vs 49%, P = 0.07). Furthermore, there was a higher incidence of grade III-IV aGVHD in the UD group compared with SD group (38% vs 24%, P = 0.002). There was no significant difference between the two groups in regard to the incidence of CMV infections, chronic GVHD (cGVHD) and relapse. At the end of the follow-up period more patients were alive among recipients of grafts from SD (48%) compared with the UD (37%, P = 0.03). The details of clinical outcomes have been described elsewhere. 14 The median ALC at day 30 was 800 × 10 6 /L vs 600 × 10 6 /L for SD and UD groups, respectively (P = 0.01). The proportion of patients with ALC304400 × 10 6 /L was higher in the SD group compared with UD group (76% vs 65%, P = 0.02).
ALC30 as a predictor of transplant outcomes
We performed a competing-risk Cox proportional hazard models for various transplant outcomes, adjusting for donor age, donor/ recipient gender and CMV status, CD34+ cell dose and HLA mismatch. As in Table 3, lower ALC30 (⩽400 × 10 6 /L) was associated with lower OS for the entire cohort with an adjustedhazard ratio (HR) of 2.30 (95% confidence interval (CI) 1.68-3.14, P ⩽ 0.0001). This was confirmed for both the SD and UD groups in separate subgroup analyses. Figure 1 displays the Kaplan-Meier curve for OS for the entire cohort based on day-30 ALC (⩽400 × 10 6 vs 4400 × 10 6 /L). Lower ALC30 (⩽400 × 10 6 /L) was associated with increased NRM for the entire cohort with a HR of 3.31 (CI 2.25-4.88, P ⩽ 0.0001), as well as for recipients of SD and UD grafts separately. Figure 2 shows the incidence of NRM for the whole cohort based on day-30 ALC (⩽400 × 10 6 vs 4400 × 10 6 /L). Furthermore, lower ALC30 (⩽400 × 10 6 /L) was associated with Low ALC30 is associated with Severe aGVHD and NRM Z Gul et al increased incidence of severe aGVHD (grade III-IV) for the entire cohort with HR of 1.99 (CI 1.32-3.00, P = 0.001), as well as for the SD and UD groups separately. Figure 3 shows the incidence of severe aGVHD (III-IV) based on day-30 ALC (⩽400 × 10 6 vs 4400 × 10 6 /L). The association between lower ALC30 and grades II-IV aGVHD was statistically significant for the whole cohort and the SD group, however, not statistically significant in the UD group. In addition, lower ALC30 was associated with more CMV reactivation in the SD group with a HR of 1.99 (CI 1.06-3.75, P = 0.03). No significant association was observed between lower day-30 ALC and relapse or cGVHD. As expected, transplant from UD, higher recipient age, and high disease risk were also associated with higher mortality in the same multivariate regression model (data not shown).
Pretransplant predictors of low day-30 ALC
We analyzed pretransplant factors in a multivariate logistic regression model for the probability of having an ALC ⩽ 400 × 10 6 /L at day 30. The model was adjusted for donor/recipient gender, CMV status, disease risk and regimen intensity. As in Table 4 , pretransplant factors significantly associated with lower day-30 ALC were HLA mismatch, UD transplant (HR of 3.03 and 2.24 respectively). Another pretransplant factor which showed significant association with lower ALC30 though with a smaller impact was CD34 counts. With each 1 million/kg increase in CD34+ cell counts, the odds of having an ALC less than 400 at day 30 decreases (HR = 0.90).
DISCUSSION
Our results confirmed the significant association of ALC30 with survival post AHSCT. To our knowledge, this is the largest cohort of AHSCT patients, analyzed for the impact of ALC30 on posttransplant outcomes with a uniform graft type and GVHD prophylaxis regimen. Furthermore, this cohort was well balanced with respect to the clinical characteristics of recipients of SD and UD grafts. We show that lower ALC30 correlated with higher risk of developing severe aGVHD, NRM and overall chance of mortality. In contrast with previous studies, the negative survival impact of low ALC30 in our cohort is not explained by higher risk of relapse. We did not detect any association between lower ALC30 (⩽400 × 10 6 /L) and risk of relapse for the whole group or the SD and UD groups separately. Furthermore, we evaluated a lower ALC value threshold of (⩽200 × 10 6 /L) and still did not find a correlation with relapse (data not shown). Therefore, the negative association of ALC30 with survival was secondary to higher NRM due predominantly to more severe aGVHD.
Previous studies have attempted to explain the association between low ALC30 and higher relapse rates based on the premise that higher ALC30 is a marker for better GVL effect. [6] [7] [8] [9] [10] Furthermore, as natural killer (NK) cells are one of the earliest subpopulation of lymphocytes to recover early post transplant, [28] [29] [30] Savani et al. 10 argued that earlier NK reconstitution resulted in better NK allo-reactivity and NK-mediated GVL. 31 NK-cell effects can target minimal residual disease, as well as Low ALC30 is associated with Severe aGVHD and NRM Z Gul et al reduce the risk of aGVHD by eliminating host Ag presenting cells. 32 This premise is hard to apply to our results, as higher ALC30 was associated only with less severe aGVHD and NRM without any association with less relapse. A plausible alternative explanation is that higher ALC30 in our cohort was associated with a higher proportion of immune suppressor lymphocytes (regulatory T or regulatory NK cells), which led to less aGVHD and NRM with no impact on relapse. One factor that distinguishes our cohort from most of the previous reports was the use of G-CSF post transplant. This might have led to a predominance of immune-suppressive cells in the ALC30. Several studies have demonstrated that G-CSF mobilizes regulatory T and NK cells into the peripheral blood, impairs T and NK TH1-type reactions and produces an immune-suppressive environment. [33] [34] [35] [36] [37] [38] [39] All patients in our cohort received G-CSF post transplant, starting from day +6 till engraftment. Interestingly our results align with those by Le Blanc et al.
11 who showed that lower ALC30 correlated with more aGVHD and NRM, with no direct correlation with relapse rates. A common feature between our study and that by Le Blanc et al. is the use of G-CSF post transplant (G-CSF was used in 62% of the patients in that report).
In addition, we show that transplant from UD or HLA mismatched donor was associated with lower ALC30. We also noted that lower CD34 cell dose had significant, though a smaller negative impact on ALC30, as have been previously reported. [40] [41] [42] [43] [44] [45] [46] Whether the lymphocyte content of the graft has an effect on ALC30 is not known, as those data were not available. As with previous reports, we acknowledge the lack of ALC30 subset analysis is a limitation of our study. Of great interest, but outside the scope of the current study, is whether low ALC30 is associated with some form of regulatory T cells deficit in transplant recipients. In summary, we report that low ALC30 post AHSCT is a strong predictor of severe aGVHD, which contributed to higher NRM and worse survival. Potential interventions to improve outcomes in patients with low ALC30 could include intensifying or prolonging immune suppression to prevent severe subsequent aGVHD. Alternatively, the low ALC30 may represent a forme fruste of sub-clinical aGVHD that might respond to corticosteroids. Cellular therapy interventions that might ameliorate the increased GVHD associated with low ALC30 include post-transplant infusions of rapamycin-resistant CD4 T-cells (enriched for regulatory T cells) or NK-cell DLI, both of which have the potential to maintain the GVL effect while limiting aGVHD. [47] [48] [49] Further studies are needed to define the critical cell phenotype of ALC30 and to better define the mechanism by which high ALC30 protects AHSCT recipients from aGVHD and NRM, thereby improving transplant outcomes. Also adjusted for donor gender, donor CMV status, recipient gender, recipient CMV status, relapse risk, intensity and any blank cells (also NS). Significant P-values are indicated in bold.
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